Brought to you by:
Will Date
Interim results of covered stent-graft hint at ‘new avenue’ in dialysis access treatment
The interim results of a first-in-human trial of a sirolimus-eluting covered stent graft—Solaris DE (Solaris Endovascular)—for the treatment of dialysis access dysfunction demonstrate the promise of the device in treating vascular access outflow stenosis, an investigator in the trial has…
EACTS 2025 hears new data on aortic arch remodelling device
Data from the AMDS PERSEVERE and PROTECT trials—both assessing the use of the Ascyrus medical dissection stent (AMDS, Artivion)—were presented in late-breaking science presentations at the 39th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting (8–11 October, Copenhagen, Denmark). The…
Learn from other fields to enhance your practice, vascular surgeon innovators told
“A lot of solutions to your problems exist in somebody else’s operating room, or somebody else’s cath lab, but you never actually go there.” These were the words of Alan B. Lumsden, MD, of the Houston Methodist Hospital in Houston,…
First-in-man results to show promise for robot-assisted HIFU in PAD treatment
Results of a first-in-human study of non-invasive, robotic-assisted high intensity focused ultrasound (HIFU) for the treatment of peripheral arterial disease (PAD), to be presented Friday morning, will show that the therapy appears to be safe and feasible for the treatment…
What the cost of cancer care teaches vascular specialists
How does the cost of treating critical limb-threatening ischemia (CLTI) in the U.S. stack up to cancer care? That was the question at the heart of research conducted by Richard W. Walsh, MD, and colleagues at the University of Texas…
CX 2025: Sirolimus implant fails to meet fistula maturation endpoint in ACCESS 2 trial
Results of the ACCESS 2 study, evaluating arteriovenous fistula (AVF) outcomes following use of the Sirogen (Vascular Therapies) sirolimus-eluting collagen implant, have shown that the device failed to meet non-inferiority for clinical fistula maturation compared to control at six months.…
ACC.25: Semaglutide improves walk distance for PAD patients with diabetes
Semaglutide significantly improved maximal walking distance in people with symptomatic peripheral arterial disease (PAD) and type 2 diabetes in a trial designed to evaluate the use of a GLP-1 agonist to manage PAD. In addition to improvements in walking ability…
One-year WAVE trial results show patency advantage for Wrapsody versus PTA
Merit Medical Systems has announced that the six-month results from the randomized arm of the Wrapsody arteriovenous access efficacy—WAVE—trial are scheduled for publication in the April issue of Kidney International, ahead of the presentation of 12-month results from the trial…
Stereotaxis seeks to broaden use of its robotic magnetic navigation system into multiple endovascular fields
Stereotaxis has announced a Food and Drug Administration (FDA) regulatory submission for the first robotically navigated catheter designed to expand usage of robotic magnetic navigation into the broader endovascular field. Emagin 5F is the first in a family of robotically…
Gore receives CE mark for lower profile Viabahn VBX endoprosthesis
Gore has announced recent CE mark of a lower profile Viabahn VBX balloon expandable endoprosthesis (VBX stent graft). Medical Device Regulation (MDR) approval of this innovation builds on a proven device which has become an important tool for treating complex…